Want to see SE:KLAR full AI Analyst Report?
KLAR Stock Chart & Stats
kr0.80
kr0.01(1.75%)
At close: 4:00 PM EDT
kr0.80
kr0.01(1.75%)
Day’s Range― - ―
52-Week Rangekr0.44 - kr1.33
Previous CloseN/A
Volume302.65K
Average Volume (3M)401.28K
Market Cap
kr211.54M
Enterprise Valuekr216.06
Total Cash (Recent Filing)kr260.00K
Total Debt (Recent Filing)kr9.70M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding245,976,150
10 Day Avg. Volume684,621
30 Day Avg. Volume401,283
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr24.00M
Bulls Say, Bears Say
Bulls Say
Platform TechnologyKlaria’s buccal thin-film delivery platform is a scalable, technology-led asset that applies across therapeutic areas. As a platform, it can be licensed to larger pharma partners, enabling recurring milestone and royalty income and reducing need for heavy commercial infrastructure if clinical validation progresses.
Meaningful Asset BaseThe balance-sheet note that 'total assets remain meaningful' indicates tangible resources and IP backing operations. These assets provide runway optionality, potential collateral for financing, and bargaining leverage in licensing talks, preserving strategic choices while pursuing partners.
Asset-Light Licensing ModelA clear partnering and licensing monetization path keeps the company asset-light and focused on R&D rather than commercial rollout. This model lowers long-term fixed costs, aligns incentives with larger collaborators, and can produce durable milestone/royalty streams once deals are secured.
Bears Say
Revenue CollapseA ~99% decline in trailing revenue represents a structural erosion of the commercial base. Sustained revenue collapse undermines internal funding capacity, reduces credibility with potential partners, and increases reliance on financing or asset disposals to sustain development programs over months.
Negative Shareholders' EquityNegative shareholders' equity is a material structural weakness that limits financial flexibility. It hampers access to debt markets, raises refinancing and covenant risks, and increases the probability of dilutive equity raises or restructuring, constraining strategic options over the medium term.
Persistent Cash BurnConsistently negative operating cash flow shows the business cannot self-fund operations and development. This persistent cash burn forces dependence on external financing or partner funding, making future program advancement and long-term planning contingent on successful capital raises.
KLAR FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was kr0.43 and its highest was kr1.33 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is kr211.54M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is Aug 27, 2026 which is in 22 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on May 29, 2026. The company reported -kr0.035 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.035.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -kr0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.38%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in SE:KLAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.